CD19 and Venous thrombosis: Of the studies published so far, Johnsrud et al. observe an incidence of 6.3% (n = 8) thrombosis within 3 months in their 127 DLBCL or B-ALL patient cohort treated with axicabtagene ciloleucel or bispecific CD19/CD22 CAR T-cells [11].